查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1518375

CAR T 細胞治療市場：按品牌、目標抗原、適應症分類 - 到2030年的全球預測

CAR T-cell Therapy Market by Brand (Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2), Indication (Lymphoma, ALL, AML, Multiple Myeloma) - Global Forecast to 2030
出版日期: | 出版商: Meticulous Research | 英文 230 Pages | 商品交期: 5-7個工作天內

價格

預計到2030年，全球 CAR T 細胞治療市場將達到 516 億美元，2023年至2030年年複合成長率為 43.3%。

本報告經過廣泛的二級和一級研究以及對市場情景的詳細分析，對關鍵行業驅動因素、限制因素、挑戰和機會進行了分析。該成長歸因於癌症發生率的增加、對 CAR T 細胞療法認識的提高以及研發活動和臨床試驗的增加。然而，複雜的製造流程和治療副作用限制該市場的成長。

此外，新興經濟體、細胞療法的技術創新以及製造流程的創新預計將為進入該市場的公司提供成長機會。然而，CAR T細胞療法的高成本、缺乏熟練的專業人員是影響市場成長的主要挑戰。

目錄

第1章 概述

第2章 研究方法

第3章 執行摘要

第4章 影響市場成長的因素

  • 摘要
  • 促進因素
    • 癌症發生率增加
    • 提高對 CAR T 細胞療法的認識
    • 研發活動及臨床試驗增加
  • 抑制因素
    • 製造流程複雜
    • 治療的副作用
  • 機會
    • 新興經濟體的前景
    • 細胞治療與製造流程的創新
  • 作業
    • 治療費用高
    • 缺乏熟練的專業人員
  • 監理分析
  • 價格分析
  • 管道產品分析
  • 病患旅程
  • 償付政策
  • 波特五力分析

第5章 全球 CAR T 細胞治療市場及趨勢分析：依品牌劃分

  • 摘要
  • Abecma（idecabtagene vicleucel）
  • Breyanzi（lisocabtagene maraleucel）
  • Kymriah（tisagenlecleucel）
  • Tecartus（brexucabtagene autoleucel）
  • Yescarta（axicabtagene ciloleucel）
  • Carvykti（ciltacabtagene autoleucel）
  • 其他品牌

第6章 全球 CAR T 細胞治療市場及趨勢分析：以標靶抗原劃分

  • 摘要
  • CD
  • BCMA
  • HER2
  • 其他標靶抗原

第7章 全球 CAR T 細胞治療市場及趨勢分析：依適應症分類

  • 摘要
  • 淋巴瘤
  • 急性淋巴性白血病
  • 多發性骨髓瘤
  • 急性骨髓性白血病
  • 其他適應症

第8章 CAR T 細胞治療市場及趨勢分析：依地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太地區其他地區
  • 拉丁美洲
  • 中東、非洲

第9章 競爭分析

  • 摘要
  • 主要成長策略
  • 供應商市場定位
  • 競爭對手儀表板
    • 行業領導者
    • 市場差異化因素
    • 領先企業
    • 新興公司
  • 市佔率分析/市場排名（2022年）

第10章 公司簡介（業務概況、財務概況、產品組合、策略發展、SWOT 分析）

  • Novartis AG
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Caribou Biosciences, Inc.
  • Cartesian Therapeutics, Inc.
  • Pfizer Inc.
  • Cellectis S.A.
  • Celyad Oncology SA
  • Gilead Sciences, Inc.
  • Intellia Therapeutics, Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Inovio Pharmaceuticals, Inc.
  • OncoTherapy Science, Inc.
  • 其他公司

第11章 附錄

Product Code: MRHC - 104824

CAR T-cell Therapy Market Size, Share, Forecast, & Trends Analysis by Brand (Abecma [idecabtagene vicleucel], Breyanzi, Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2) Indication (Lymphoma, ALL, AML)-Global Forecast to 2030.

The global CAR T-cell Therapy market is projected to reach $51.6 billion by 2030 at a CAGR of 43.3% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. This growth is due to increasing cancer prevalence, rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy restrain the growth of this market.

Furthermore, the scope in emerging economies, innovation in cell therapies, and manufacturing processes are expected to generate growth opportunities for the players operating in this market. However, high cost of CAR T-cell therapy, and lack of skilled professionals are major challenges impacting market growth.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2023). The key players operating in the global CAR T-cell Therapy market are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).

Among all the drug types studied in this report, in 2023, the Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-cell therapy market. Yescarta (axicabtagene ciloleucel) has demonstrated superior effectiveness compared to other treatments. It exhibits high efficacy in treating high-grade B-cell lymphoma (HGBL), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal large B-cell lymphoma (PMBCL) that have not responded to previous therapies, establishing its dominance in the CAR T-cell therapy market.

Among all the target antigens studied in this report, in 2023, CD target antigen segment is projected to register the highest CAGR during the forecast period due to strong product pipeline, the increasing clinical trials focusing on the CD antigen therapies, and the ongoing research studies to develop the therapies focusing on the CD target antigen.

Among all the indications studied in this report, in 2023, the lymphoma segment is expected to account for the largest share of the CAR T-Cell therapy market. Lymphoma is a group of blood cancers that develop from abnormal white blood cells or lymphocytes. Due to the increased cases of lymphoma, there was a rise in the adoption of CAR T-cell therapy for treating lymphoma, contributing to the large share of this segment.

An in-depth analysis of the geographical scenario of the global CAR T-cell therapy market provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the CAR T-cell Therapy market. In 2023, the U.S. is expected to account for the largest share of the CAR T-cell Therapy market in North America. The large share of this regional market is attributed to the presence of major CAR T-cell Therapy companies such as bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), and Caribou Biosciences, Inc. (U.S.), increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials in the region.

Scope of the Report:

CAR T-cell Therapy Market Assessment-by Drug Type

  • Abecma (idecabtagene vicleucel)
  • Breyanzi (lisocabtagene maraleucel)
  • Kymriah (tisagenlecleucel)
  • Tecartus (brexucabtagene autoleucel)
  • Yescarta (axicabtagene ciloleucel)
  • Carvykti (ciltacabtagene autoleucel)
  • Other Brands

CAR T-cell Therapy Market Assessment-by Target Antigen

  • CD
  • BCMA
  • HER2
  • Other Target Antigens

Note: Other target antigens include EGFR, GD2, MUC16, Lewis Y, and ROR1

CAR T-cell Therapy Market Assessment-by Indication

  • Lymphoma
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • Acute Myeloid Leukemia
  • Other Indications

Note: Other indications include pancreatic cancer, breast cancer, ovarian cancer, scleroderma, HIV/AIDs, and autoimmune diseases.

CAR T-cell Therapy Market Assessment-by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Overview

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitation
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
  • 2.3. Market Sizing and Forecast
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Factors Affecting Market Growth

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. Increasing Cancer Prevalence
    • 4.2.2. Rise in Awareness Regarding CAR T-cell Therapy
    • 4.2.3. Increasing R&D Activities and Clinical Trials
  • 4.3. Restraints
    • 4.3.1. Complex Manufacturing Process
    • 4.3.2. Adverse Effects of the Therapy
  • 4.4. Opportunities
    • 4.4.1. Scope in Emerging Economies
    • 4.4.2. Innovation in Cell Therapies and Manufacturing Processes
  • 4.5. Challenges
    • 4.5.1. High Cost of Therapy
    • 4.5.2. Lack of Skilled Professionals
  • 4.6. Regulatory Analysis
  • 4.7. Pricing Analysis
  • 4.8. Pipeline Product Analysis
  • 4.9. Patient Journey
  • 4.10. Reimbursement Policies
  • 4.11. Porters Five Forces Analysis

5. Global CAR T-cell Therapy Market & Trend Analysis-by Brand

  • 5.1. Overview
  • 5.2. Abecma (idecabtagene vicleucel)
  • 5.3. Breyanzi (lisocabtagene maraleucel)
  • 5.4. Kymriah (tisagenlecleucel)
  • 5.5. Tecartus (brexucabtagene autoleucel)
  • 5.6. Yescarta (axicabtagene ciloleucel)
  • 5.7. Carvykti (ciltacabtagene autoleucel)
  • 5.8. Other Brands

6. Global CAR T-cell Therapy Market & Trend Analysis-by Target Antigen

  • 6.1. Overview
  • 6.2. CD
  • 6.3. BCMA
  • 6.4. HER2
  • 6.5. Other Target Antigens

7. Global CAR T-cell Therapy Market & Trend Analysis-by Indication

  • 7.1. Overview
  • 7.2. Lymphoma
  • 7.3. Acute Lymphoblastic Leukemia
  • 7.4. Multiple Myeloma
  • 7.5. Acute Myeloid Leukemia
  • 7.6. Other Indications

8. CAR T-cell Therapy Market & Trend Analysis-by Geography

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. France
    • 8.3.3. U.K.
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Rest of Asia-Pacific
  • 8.5. Latin America
  • 8.6. Middle East & Africa

9. Competitive Analysis

  • 9.1. Overview
  • 9.2. Key Growth Strategies
  • 9.3. Vendor Market Positioning
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share Analysis/Market Ranking (2022)

10. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)

  • 10.1. Novartis AG
  • 10.2. bluebird bio, Inc.
  • 10.3. Bristol-Myers Squibb Company
  • 10.4. Caribou Biosciences, Inc.
  • 10.5. Cartesian Therapeutics, Inc.
  • 10.6. Pfizer Inc.
  • 10.7. Cellectis S.A.
  • 10.8. Celyad Oncology SA
  • 10.9. Gilead Sciences, Inc.
  • 10.10. Intellia Therapeutics, Inc.
  • 10.11. Merck & Co., Inc.
  • 10.12 Amgen Inc.
  • 10.13. Inovio Pharmaceuticals, Inc.
  • 10.14. OncoTherapy Science, Inc.
  • 10.15. Other Companies

11. Appendix

  • 11.1. Questionnaire
  • 11.2. Available Customization

LIST OF TABLES

  • Table 1 Global CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 2 Global CAR T-cell Therapy Market for Abecma (idecabtagene vicleucel), by Country/Region, 2021-2030 (USD Million)
  • Table 3 Global CAR T-cell Therapy Market for Breyanzi (lisocabtagene maraleucel), by Country/Region, 2021-2030 (USD Million)
  • Table 4 Global CAR T-cell Therapy Market for Kymriah (tisagenlecleucel), by Country/Region, 2021-2030 (USD Million)
  • Table 5 Global CAR T-cell Therapy Market for Tecartus (brexucabtagene autoleucel), by Country/Region, 2021-2030 (USD Million)
  • Table 6 Global CAR T-cell Therapy Market for Yescarta (axicabtagene ciloleucel), by Country/Region, 2021-2030 (USD Million)
  • Table 7 Global CAR T-cell Therapy Market for Carvykti (ciltacabtagene autoleucel), by Country/Region, 2021-2030 (USD Million)
  • Table 8 Global CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 9 Global CD Antigen Market, by Country/Region, 2021-2030 (USD Million)
  • Table 10 Global BCMA Antigen Market, by Country/Region, 2021-2030 (USD Million)
  • Table 11 Global HER2 Antigen Market, by Country/Region, 2021-2030 (USD Million)
  • Table 12 Global Other Target Antigens Market, by Country/Region, 2021-2030 (USD Million)
  • Table 13 Global CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 14 Global CAR T-cell Therapy Market for Lymphoma, by Country/Region, 2021-2030 (USD Million)
  • Table 15 Global CAR T-cell Therapy Market for Acute Lymphoblastic Leukemia, by Country/Region, 2021-2030 (USD Million)
  • Table 16 Global CAR T-cell Therapy Market for Multiple Myeloma, by Country/Region, 2021-2030 (USD Million)
  • Table 17 Global CAR T-cell Therapy Market for Acute Myeloid Leukemia, by Country/Region, 2021-2030 (USD Million)
  • Table 18 Global CAR T-cell Therapy Market for Other Indications, by Country/Region, 2021-2030 (USD Million)
  • Table 19 North America: CAR T-cell Therapy Market, by Country, 2021-2030 (USD Million)
  • Table 20 North America: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 21 North America: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 22 North America: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 23 U.S.: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 24 U.S.: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 25 U.S.: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 26 Canada: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 27 Canada: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 28 Canada: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 29 Europe: CAR T-cell Therapy Market, by Country/Region, 2021-2030 (USD Million)
  • Table 30 Europe: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 31 Europe: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 32 Europe: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 33 Germany: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 34 Germany: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 35 Germany: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 36 France: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 37 France: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 38 France: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 39 U.K.: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 40 U.K.: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 41 U.K.: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 42 Italy: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 43 Italy: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 44 Italy: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 45 Spain: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 46 Spain: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 47 Spain: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 48 Rest of Europe: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 49 Rest of Europe: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 50 Rest of Europe: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 51 Asia-Pacific: CAR T-cell Therapy Market, by Country/Region, 2021-2030 (USD Million)
  • Table 52 Asia-Pacific: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 53 Asia-Pacific: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 54 Asia-Pacific: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 55 China: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 56 China: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 57 China: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 58 Japan: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 59 Japan: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 60 Japan: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 61 India: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 62 India: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 63 India: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 64 Rest of Asia-Pacific: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 65 Rest of Asia-Pacific: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 66 Rest of Asia-Pacific: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 67 Latin America: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 68 Latin America: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 69 Latin America: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 70 Middle East & Africa: CAR T-cell Therapy Market, by Brand, 2021-2030 (USD Million)
  • Table 71 Middle East & Africa: CAR T-cell Therapy Market, by Target Antigen, 2021-2030 (USD Million)
  • Table 72 Middle East & Africa: CAR T-cell Therapy Market, by Indication, 2021-2030 (USD Million)
  • Table 73 Recent Developments, by Company, 2020-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
  • Figure 6 Market Size Estimation
  • Figure 7 Global CAR T-cell Therapy Market, by Brand, 2024 VS. 2030 (USD Million)
  • Figure 8 Global CAR T-cell Therapy Market, by Target Antigen, 2024 VS. 2030 (USD Million)
  • Figure 9 Global CAR T-cell Therapy Market, by Indication, 2024 VS. 2030 (USD Million)
  • Figure 10 CAR T-cell Therapy Market, by Region
  • Figure 11 Impact Analysis: CAR T-cell Therapy Market
  • Figure 12 Market Dynamics: CAR T-cell Therapy Market
  • Figure 13 Global CAR T-cell Therapy Market, by Brand, 2024 VS. 2030 (USD Million)
  • Figure 14 Global CAR T-cell Therapy Market, by Target Antigen, 2024-2030 (USD Million)
  • Figure 15 Global CAR T-cell Therapy Market, by Indication, 2024-2030 (USD Million)
  • Figure 16 Global CAR T-cell Therapy Market, by Geography, 2024-2030 (USD Million)
  • Figure 17 North America: CAR T-cell Therapy Market Snapshot
  • Figure 18 Europe: CAR T-cell Therapy Market Snapshot
  • Figure 19 Asia-Pacific: CAR T-cell Therapy Market Snapshot
  • Figure 20 Key Growth Strategies Adopted by Leading Players, 2020-2024
  • Figure 21 Competitive Dashboard: Chromatography Data Systems Market
  • Figure 22 CAR T-cell Therapy Market: Competitive Benchmarking, by Target Antigen
  • Figure 23 Novartis AG: Financial Overview (2022)
  • Figure 24 bluebird bio, Inc.: Financial Overview (2021)
  • Figure 25 Bristol-Myers Squibb Company: Financial Overview (2021)
  • Figure 26 Cellectis S.A.: Financial Overview (2021)
  • Figure 27 Caribou Biosciences, Inc.: Financial Overview (2021)
  • Figure 28 Pfizer Inc.: Financial Overview (2021)
  • Figure 29 Celyad Oncology SA: Financial Overview (2022)
  • Figure 30 Gilead Sciences, Inc.: Financial Overview (2022)
  • Figure 31 Intellia Therapeutics, Inc.: Financial Overview (2021)
  • Figure 32 Merck & Co., Inc.: Financial Overview (2022)
  • Figure 33 Amgen Inc.: Financial Overview (2022)
  • Figure 34 Inovio Pharmaceuticals, Inc.: Financial Overview (2022)
  • Figure 35 OncoTherapy Science, Inc.: Financial Overview (2022)